Nektar Therapeutics
NKTR
244 hedge funds and large institutions have $3.19B invested in Nektar Therapeutics in 2020 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 85 increasing their positions, 83 reducing their positions, and 57 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 83
0.15% less ownership
Funds ownership: 100.02% → 99.87% (-0.15%)
13% less funds holding
Funds holding: 281 → 244 (-37)
16% less capital invested
Capital invested by funds: $3.8B → $3.19B (-$614M)
37% less call options, than puts
Call options by funds: $12.8M | Put options by funds: $20.2M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
56% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$94.4M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$47.3M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
+$34.2M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$11M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$9.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$34.1M |
| 2 |
Janus Henderson Group
London,
|
-$22M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$18.5M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$15.5M |
| 5 |
Millennium Management
New York
|
-$10.7M |
NKTR Hedge Fund Activity: Q1 2020 in Review
244 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2020, worth a combined $3.19B — down 16% from $3.8B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of NKTR and 25 opened new positions — a net loss of 32 holders — while 83 trimmed existing stakes and 85 added.
The largest buyer was Fidelity Investments, adding an estimated $94.4M. The largest seller was JP Morgan Chase, cutting an estimated $34.1M.
- 244 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2020, down from 281 in Q4 2019.
- Funds reported $3.19B of Nektar Therapeutics stock for Q1 2020, down 16% quarter-over-quarter.
- 25 funds opened new Nektar Therapeutics positions in Q1 2020 and 57 closed out, a net change of -32 holders.
- The largest Nektar Therapeutics buyer in Q1 2020 was Fidelity Investments, an estimated $94.4M added.
- The largest Nektar Therapeutics seller in Q1 2020 was JP Morgan Chase, an estimated $34.1M sold.
Based on aggregated 13F filings for Q1 2020.